Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diprophylline (also known as dyphylline) is a xanthine derivative and theophylline analog with bronchodilator and vasodilator properties. It is primarily used in the treatment of respiratory disorders such as asthma, chronic bronchitis, emphysema, and cardiac dyspnea. Diprophylline acts mainly by antagonizing adenosine receptors and inhibiting phosphodiesterase enzymes (notably type III or IV), leading to increased cyclic AMP levels in smooth muscle cells. This results in relaxation of bronchial smooth muscle and dilation of airways. Additional effects include mild diuretic action and stimulation of the central nervous system's respiratory centers[2][5][6]. The drug is administered orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diprophylline.